Author:
Tanem Kristine Eidal,Stensvold Einar,Wilberg Petter,Skaare Anne B.,Brandal Petter,Herlofson Bente Brokstad
Abstract
Abstract
Purpose
To investigate oral and dental late effects in survivors of childhood brain tumors medulloblastoma (MB) and central nervous system supratentorial primitive neuroectodermal tumor (CNS-PNET).
Methods
This cross-sectional study assessed oral and dental late effects in MB/CNS-PNET survivors treated before 20 years of age, and with a minimum of 2 years since treatment. Participants went through an oral and radiographic examination. We assessed oral status using the decayed-missing-filled index (DMFT), oral dryness, maximum mouth opening (MMO), fungal infection, and registration of dental developmental disturbances (DDD) in the form of hypodontia, microdontia, and enamel hypoplasia.
Results
The 46 participants’ mean age at enrolment was 27 ± 12.8 years and at treatment 8.5 ± 5.2 years, and the mean time since treatment was 18.9 ± 12 years. Over a third (35%) of survivors had reduced mouth opening (mean 29.3 ± 5.6 mm (range 16–35)). A significantly lower MMO was found in individuals treated ≤ 5 years compared to survivors treated > 5 years (p = 0.021). One or more DDD were registered in 30.4% of the survivors, with a significantly higher prevalence in individuals treated ≤ 5 years (p < 0.001). Hypodontia was the most prevalent type of DDD. There was no difference in DMFT score in relation to age at treatment. Oral dryness was not frequently reported or observed in these survivors.
Conclusion
Survivors of childhood MB/CNS-PNET are at risk of oral and dental late effects including reduced mouth opening and DDD. The risk is highest in survivors treated before the age of 5.
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. King AA, Seidel K, Di C, Leisenring WM, Perkins SM, Krull KR, Sklar CA, Green DM, Armstrong GT, Zeltzer LK, Wells E, Stovall M, Ullrich NJ, Oeffinger KC, Robison LL, Packer RJ (2017) Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the childhood cancer survivor study. Neuro Oncol 19(5):689–698
2. Stensvold E (2020) Paediatric and adolescent medulloblastoma and CNS-PNET in Norway 1974–2013: survival, regional differences, and late effects. [Dissertation]. University of Oslo, Oslo, p 25–28
3. Salloum R, Chen Y, Yasui Y, Packer R, Leisenring W, Wells E, King A, Howell R, Gibson TM, Krull KR, Robinson LL, Oeffinger Kobel C, Foulandi M, Armstrong GT (2019) Late morbidity and mortality among medulloblastoma survivors diagnosed across three decades: a report from the childhood cancer survivor study. J Clin Oncol 37(9):731–740
4. Millard NE, De Branganca KC (2016) Medulloblastoma. J Child Neurol 31(12):1341–1353
5. Stensvold E, Krossnes BK, Lundar T, Due-Tønnessen BJ, Fric R, Due-Tønnessen P, Bechensteen AG, Myklebust TÅ, Johannesen TB, Brandal P (2017) Outcome for children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor (CNS-PNET)- a retrospective analysis spanning 40 years of treatment. Acta Oncol 56:698–705
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献